NAV Stock Overview
Researches, develops, manufactures, and commercializes nanotechnology products and materials. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
My Notes
Capture your thoughts, links and company narrative
NAVCO Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.015 |
| 52 Week High | CA$0.12 |
| 52 Week Low | CA$0.01 |
| Beta | 0 |
| 1 Month Change | -25.00% |
| 3 Month Change | -70.00% |
| 1 Year Change | -40.00% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | n/a |
Recent News & Updates
Recent updates
Shareholder Returns
| NAV | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 0% | -3.6% | -2.6% |
| 1Y | -40.0% | 12.9% | 15.2% |
Return vs Industry: NAV underperformed the Canadian Biotechs industry which returned 11.5% over the past year.
Return vs Market: NAV underperformed the Canadian Market which returned 15.2% over the past year.
Price Volatility
| NAV volatility | |
|---|---|
| NAV Average Weekly Movement | 60.5% |
| Biotechs Industry Average Movement | 13.4% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CA Market | 17.4% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: NAV's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: NAV's weekly volatility (61%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Geoffrey Lee | navcopharma.com |
NAVCO Pharmaceuticals Inc. researches, develops, manufactures, and commercializes nanotechnology products and materials. It offers aerosol spray, hand cream and sanitizer, and colloidal silver products. The company also provides COVID PCR testing, PPE, and diagnostic PCR testing, as well as textile and food solutions.
NAVCO Pharmaceuticals Inc. Fundamentals Summary
| NAV fundamental statistics | |
|---|---|
| Market cap | CA$856.04k |
| Earnings (TTM) | CA$489.32k |
| Revenue (TTM) | n/a |
1.7x
P/E Ratio0.0x
P/S RatioIs NAV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NAV income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | -CA$489.32k |
| Earnings | CA$489.32k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0086 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 3,488.3% |
How did NAV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 12:31 |
| End of Day Share Price | 2024/12/17 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NAVCO Pharmaceuticals Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|